Phase Ib/II ECHO-202/KEYNOTE-037: Epacadostat + Pembrolizumab in Pts With Advanced Urothelial Carcinoma

June 2-6, 2017; Chicago, Illinois
In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.
Format: Microsoft PowerPoint (.ppt)
File Size: 579 KB
Released: June 14, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Slides from Clinical Care Options (CCO) on histology-agnostic biomarker testing to guide therapy for gastrointestinal cancer

John L. Marshall, MD Released: July 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue